Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Non Operating Income (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Non Operating Income for 7 consecutive years, with $832000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 2.35% year-over-year to $832000.0, compared with a TTM value of $3.5 million through Dec 2025, down 9.97%, and an annual FY2025 reading of $3.5 million, down 9.97% over the prior year.
  • Non Operating Income was $832000.0 for Q4 2025 at aTYR PHARMA, down from $999000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $1.3 million in Q3 2023 and bottomed at $47000.0 in Q1 2021.
  • Average Non Operating Income over 5 years is $660850.0, with a median of $833500.0 recorded in 2023.
  • The sharpest move saw Non Operating Income soared 1480.0% in 2021, then crashed 30.71% in 2024.
  • Year by year, Non Operating Income stood at $79000.0 in 2021, then soared by 440.51% to $427000.0 in 2022, then skyrocketed by 180.56% to $1.2 million in 2023, then fell by 28.88% to $852000.0 in 2024, then dropped by 2.35% to $832000.0 in 2025.
  • Business Quant data shows Non Operating Income for ATYR at $832000.0 in Q4 2025, $999000.0 in Q3 2025, and $781000.0 in Q2 2025.